Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thomas Otten
Observed names:
Otten, Thomas,
T. Otten,
Thomas M. Otten,
Thomas Michael Otten
Institution:
National Institute for Public Health and the Environment
Observed institutions:
Maastricht University Medical Centre,
Maastricht University,
National Institute for Public Health and the Environment,
Care and Public Health Research Institute,
Erasmus University Rotterdam
ORCID:
0000-0002-6390-5638
Observed ORCID:
0000-0002-6390-5638
OpenAlex ID:
A5041959705
COVID-19 Pandemic in the United States
2020
·
Savannah Bergquist
, Thomas Otten
, et al.
·
Health Policy and Technology
·
191
PDF
Finding the way forward: COVID-19 vaccination progress in Germany, Austria and Switzerland
2021
·
Zachary Desson
, Lukas Kauer
, et al.
·
Health Policy and Technology
·
51
PDF
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
2023
·
Thomas Michael Otten
, Sabine E. Grimm
, et al.
·
PharmacoEconomics
·
32
PDF
Headroom Analysis for Early Economic Evaluation: A Systematic Review
2022
·
Esther A. Boudewijns
, Thomas M. Otten
, et al.
·
Applied Health Economics and Health Policy
·
16
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
2022
·
Ben Wijnen
, Willem Witlox
, et al.
·
PharmacoEconomics
·
9
PDF
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
2021
·
Sabine E. Grimm
, Xavier Pouwels
, et al.
·
PharmacoEconomics
·
9
PDF
Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
2022
·
Thomas Otten
, Rob Riemsma
, et al.
·
PharmacoEconomics
·
7
PDF
Forecasting the value of innovation in total knee arthroplasty care: A headroom approach
2024
·
Thomas M. Otten
, Sabine E. Grimm
, et al.
·
Journal of Experimental Orthopaedics
·
3
PDF
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
2023
·
Willem Witlox
, Sabine Grimm
, et al.
·
PharmacoEconomics
·
3
PDF
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
2024
·
Bradley M. Sugden
, Sabine E. Grimm
, et al.
·
PharmacoEconomics
·
2
Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
2023
·
Thomas Otten
, Rob Riemsma
, et al.
·
PharmacoEconomics
·
1
PDF
Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands
2026
·
Thomas Otten
, Mirjam Knol
, et al.
·
BMC Medicine
Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands
2026
·
Otten, Thomas
, Knol, Mirjam
, et al.
·
Figshare
HTA188 The Potential Value of Health Technologies Postponing Total Knee Replacements While Increasing Patients’ Quality of Life
2023
·
T. Otten
, B. Ramaekers
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
17
Citation count:
324
H-index:
7
I10-index:
4
Year
Topic
Type